Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of CNBX Pharmaceuticals Inc. from 30 Nov 2018 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
CNBX Pharmaceuticals Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Nov 2018 to 30 Nov 2025.
  • CNBX Pharmaceuticals Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 30 Nov 2025 was $7,408, a 18% increase year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)

CNBX Pharmaceuticals Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $7,408 +$1,669 +18% 01 Sep 2025 30 Nov 2025 10-Q 14 Jan 2026 2026 Q1
Q4 2024 $9,077 +$38,972 +81% 01 Sep 2024 30 Nov 2024 10-Q 14 Jan 2026 2026 Q1
Q4 2023 $48,049 01 Sep 2023 30 Nov 2023 10-Q 13 Jan 2025 2025 Q1
Q4 2019 $53,362 -$5,132,938 -99% 01 Sep 2019 30 Nov 2019 10-Q 14 Jan 2020 2020 Q1
Q4 2018 $5,186,300 01 Sep 2018 30 Nov 2018 10-Q 14 Jan 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.